Elicio Therapeutics (ELTX) Total Liabilities (2020 - 2026)

Elicio Therapeutics (ELTX) has reported Total Liabilities for 7 consecutive years, with $23.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities fell 15.53% year-over-year to $23.4 million; the trailing twelve-month figure through Jun 2026 stood at $23.4 million (down 15.53% YoY), and the FY2025 full-year result was $24.2 million, down 38.65% from the prior year.
• Total Liabilities slipped to $23.4 million in Q2 2026 per ELTX's latest filing, from $24.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $57.4 million in Q3 2024 and bottomed at $2.1 million in Q1 2023.
• Historically, Total Liabilities has averaged $20.9 million across 5 years, with a median of $18.5 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Total Liabilities plunged 85.05% in 2023, then jumped 833.37% in 2024.
• Over 5 years, Total Liabilities stood at $13.7 million in 2022, then increased by 14.72% to $15.8 million in 2023, then soared by 150.36% to $39.5 million in 2024, then plunged by 38.65% to $24.2 million in 2025, then declined by 3.44% to $23.4 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $23.4 million, $24.1 million, and $24.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.